ristocetin and Hemorrhagic-Fever--American

ristocetin has been researched along with Hemorrhagic-Fever--American* in 1 studies

Other Studies

1 other study(ies) available for ristocetin and Hemorrhagic-Fever--American

ArticleYear
A plasma inhibitor of platelet aggregation in patients with Argentine hemorrhagic fever.
    The American journal of tropical medicine and hygiene, 1990, Volume: 42, Issue:5

    Hemorrhage in patients with Lassa fever is associated with the presence of a circulating plasma inhibitor of platelet aggregation. This study was to determine whether patients with Argentine hemorrhagic fever (AHF) develop a similar inhibitor. Normal platelets showed significantly weaker aggregation responses to a sub-maximal dose of adenosine diphosphate (ADP) when mixed with plasma from 10 patients with AHF (mean percent of control +/- 1 SE = 57.2 +/- 6.7%) compared to those mixed with plasma from 9 viral control patients (79.5 +/- 4.1%; P less than 0.05) and 9 febrile patients with septicemia (103.8 +/- 3%; P less than 0.001). Plasma from 3 patients with severe AHF inhibited in a dose-dependent fashion the aggregation responses of normal platelets to collagen, sodium arachidonate, a calcium ionophore (A23187), and ristocetin; none of 4 samples from convalescent AHF patients showed this inhibitory activity. The platelet inhibition was sudden in onset and unaffected by a 30 min pre-incubation, not neutralized by convalescent plasma with high titer antibody to Junin virus, and abolished after heating plasma from an AHF patient at 56 degrees C for 30 min. Hemorrhage in AHF is associated with the presence of a circulating inhibitor of platelet aggregation, and disturbed hemostasis in arenavirus-induced hemorrhagic fevers may have a common basis.

    Topics: Adenosine Diphosphate; Antibodies, Viral; Arachidonic Acid; Arachidonic Acids; Arenaviruses, New World; Calcimycin; Collagen; Hemorrhagic Fever, American; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ristocetin; Temperature

1990